Thetis Pharmaceuticals LLC (“Thetis”), a clinical-stage company developing TP-317, a first-in-class, small molecule drug ...

CJRB-201', a proprietary strain of Faecalibacterium with potent its anti-inflammatory effects, has demonstrated the strongest ...

“The preclinical results demonstrate ... Therapy in Inflammatory Bowel Disease (IBD): Translating Resolvin E1 Activation of BLT1 in Experimental Models to Healthy Volunteers Abstract Number ...

Preclinical studies in multiple animal models confirm significant improvements ... for the treatment of inflammatory bowel disease (IBD). The company has selected CJRB-201 as the next drug ...

Preclinical studies in multiple animal models confirm significant improvements ... conference in the field of inflammatory bowel disease (IBD), attracting gastroenterologists, researchers, and ...